Oncology
Clinical research is centred on solid tumours, with attention to tumour-directed treatment strategies in patients with advanced cancer.
- Solid tumour therapeutics
- Anti-cancer treatment development
- Tumour-specific intervention
The sponsor’s active trial portfolio reflects interest in therapies intended for malignant tumour types and cancer treatment settings.
Immuno-oncology
Research activity includes combination strategies involving PD-1 and PD-L1 inhibitors, indicating a focus on immune-based cancer treatment.
- Checkpoint inhibition
- Immune-modulating cancer therapy
- Combination oncology regimens
Interest in pairing tumour-directed agents with immune checkpoint blockade places immunotherapy within the sponsor’s therapeutic scope.
Early clinical development
The funded programme is focused on initial clinical evaluation of a new oncology candidate, with emphasis on treatment safety and tolerability in people with cancer.
- First-in-patient oncology research
- Safety assessment
- Tolerability evaluation
Clinical activity spans multiple research sites across two countries, supporting investigation in an international cancer research setting.
